Dr. Charles M. Rudin highlighted new small cell lung cancer therapies, including T cell engagers, antibody-drug conjugates, ...

The phase 2 SANRECO study has recently completed enrollment and will evaluate divesiran, a potential therapy for patients ...

Voranigo (vorasidenib), a drug for certain brain tumors, was safe and well toleratedin patients with grade 3 or 4 IDH-mutant ...

Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell ...

Grief intertwines with holiday traditions, creating a complex emotional landscape where joy and sorrow coexist, reflecting the depth of love and loss. The natural human process of grief is intensified ...

In observation of Neuroendocrine Tumors (NETs) Awareness Month, Dr. Pamela L. Kunz sat down for an interview with CURE to ...

Panelists discuss how patients beginning talquetamab should maintain a positive attitude, prepare thoroughly with educational ...

Panelists discuss how healthcare providers can develop comprehensive management protocols for talquetamab-related toxicities ...

Panelists discuss how effective caregivers should join support groups, maintain detailed records of symptoms and medications, ...

Dr. Pamela L. Kunz sat down for an interview with CURE to discuss resources and ongoing initiatives that may help patients with this disease.

Panelists discuss how specific talquetamab-related side effects like skin peeling, nail changes, and rashes can be effectively managed through targeted interventions including topical treatments, ...

Panelists discuss how successful talquetamab treatment requires coordinated care between inpatient and outpatient teams, comprehensive caregiver preparation including education materials and emergency ...